Literature DB >> 31704273

Alpha-asarone improves cognitive function of aged rats by alleviating neuronal excitotoxicity via GABAA receptors.

Yu Chen1, Xiaofeng Gao1, Qi Liu1, Lili Zeng1, Kun Zhang1, Keman Mu1, Di Zhang1, Huixi Zou1, Nan Wu1, Jierui Ou2, Qiantao Wang3, Shengjun Mao4.   

Abstract

Alzheimer's disease (AD), the most common form of dementia, still lacks effective treatment at present. Alpha-asarone (ASA) is the major compound isolated from the Chinese medicinal herb Acorus gramineus. It has been reported to enhance cognitive function in rodent models, yet its mechanism was not fully understood. In this work, we demonstrated that ASA improved the spatial memory, reduced the neuronal injury, and decreased the level of Aβ1-42 in the hippocampus of aged rats. The results also showed that ASA had the neuroprotective effects against glutamate toxicity and decreased cytoplasmic calcium level in primary hippocampal neurons. By comparing the multiple properties of ASA and propofol (PPF) via computer modelling, we speculated that ASA may bind to the PPF binding site of type A gamma (γ)-aminobutyric acid receptors (GABAARs). This was further supported by the whole-cell patch-clamp recording. Our results suggested that ASA, as a GABAAR positive allosteric modulator (PAM), can improve cognitive function of aged rats by alleviating the neuronal overexcitation. Furthermore, the binding mode of ASA on GABAAR may lay a foundation for structure-based drug design in AD therapy.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Asarone; Cognitive deficits; Gamma-aminobutyric acid; Neuronal overexcitation; Positive allosteric modulator

Mesh:

Substances:

Year:  2019        PMID: 31704273     DOI: 10.1016/j.neuropharm.2019.107843

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  5 in total

1.  Comprehensive Quality Assessment of Kaixin Powder by HPLC-DAD Quantification and HPLC-QTOF-MS/MS Confirmation.

Authors:  Binbin Wang; Xiaoxiao Feng; Sihan Liu; Feng Qiu; Xuran Lu; Zhaoxia Li
Journal:  ACS Omega       Date:  2021-04-21

Review 2.  GABAergic Inhibitory Interneuron Deficits in Alzheimer's Disease: Implications for Treatment.

Authors:  Yilan Xu; Manna Zhao; Yuying Han; Heng Zhang
Journal:  Front Neurosci       Date:  2020-06-30       Impact factor: 4.677

Review 3.  Molecular Mechanisms and Therapeutic Potential of α- and β-Asarone in the Treatment of Neurological Disorders.

Authors:  Rengasamy Balakrishnan; Duk-Yeon Cho; In-Su Kim; Sang-Ho Seol; Dong-Kug Choi
Journal:  Antioxidants (Basel)       Date:  2022-01-29

4.  Alpha-Asaronol Alleviates Dysmyelination by Enhancing Glutamate Transport Through the Activation of PPARγ-GLT-1 Signaling in Hypoxia-Ischemia Neonatal Rats.

Authors:  Yuhang Ge; Fei Zhen; Ziqi Liu; Zhaowei Feng; Gui Wang; Chu Zhang; Xingqi Wang; Ying Sun; Xiaohui Zheng; Yajun Bai; Ruiqin Yao
Journal:  Front Pharmacol       Date:  2022-03-23       Impact factor: 5.810

Review 5.  The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases.

Authors:  Wioletta Rozpędek-Kamińska; Natalia Siwecka; Adam Wawrzynkiewicz; Radosław Wojtczak; Dariusz Pytel; J Alan Diehl; Ireneusz Majsterek
Journal:  Int J Mol Sci       Date:  2020-03-19       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.